Clinical Trial

A Long-term Trial of EB-1020 in Adult Patients With ADHD

Name: A Long-term Trial of EB-1020 in Adult Patients With ADHD — clinical trial record (NCT06926829)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the safety of long-term administration of mainly high doses of EB-1020 over 52 weeks in patients who have completed the double-blind trial (405-102-00112) conducted in Japan

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-04-11.

Trial Details

NCT Number	NCT06926829
Lead Sponsor	Otsuka Pharmaceutical Co., Ltd.
Conditions	Attention Deficit Hyperactivity Disorder (ADHD)
Enrollment	180 participants
Start Date	2025-06-25
Primary Completion	2027-12 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2025-08-03